Your activity: 7422 p.v.
your limit has been reached. plz Donate us to allow your ip full access, Email: [email protected]

Overview of treatment of chronic wounds

Overview of treatment of chronic wounds
Authors:
Karen Evans, MD
Paul J Kim, DPM, MS
Section Editors:
Charles E Butler, MD, FACS
Russell S Berman, MD
Eduardo Bruera, MD
Deputy Editors:
Kathryn A Collins, MD, PhD, FACS
Diane MF Savarese, MD
Literature review current through: Feb 2022. | This topic last updated: Sep 01, 2020.

INTRODUCTION — A chronic wound may be defined as one that is physiologically impaired due to a disruption of the wound healing cycle as a result of impaired angiogenesis, innervation, or cellular migration, among other reasons [1]. Normal wound healing is described separately. (See "Risk factors for impaired wound healing and wound complications", section on 'Impaired wound healing'.)

The precise timeline for complete epithelialization varies depending on numerous factors, including comorbidities (eg, diabetes, autoimmune disease, peripheral artery disease), increased body mass index, anatomic location, and medications. However, regardless of etiology, wound healing normally progresses at a sustained, measurable rate. Although there is no specific time frame that clearly differentiates an acute from a chronic wound, some suggest that the lack of approximately 15 percent reduction weekly or approximately 50 percent reduction of the surface area of the wound over a one-month period indicates a chronic state [2].

Examples of chronic wounds include nonhealing or infected surgical or traumatic wounds, venous ulcers, pressure ulcers, diabetic foot ulcers, and ischemic ulcers. Chronic wounds related to malignancy require appropriate treatment of the malignancy, but in some cases, palliation may be all that can be offered [3,4]. The clinical assessment and differentiation of these wounds is reviewed elsewhere. (See "Clinical assessment of chronic wounds".)

LOCAL CARE OF CHRONIC WOUNDS — Local treatment is directed toward reducing pain and itching, minimizing infection and bleeding from the wound, and dealing with the most troublesome chronic wound problems that affect the patient physically and emotionally, such as excess exudate that can lead to unpleasant odors.

As with acute wounds, local care of chronic wounds includes debridement and proper wound dressings. Frankly necrotic debris should be aggressively removed. Proper local care is an important element of preparing the wound bed to accept a skin graft or flap, or for closure, when indicated. (See "Basic principles of wound management", section on 'Wound debridement' and "Basic principles of wound management", section on 'Wound dressings' and 'Wound bed preparation' below.)

Odor — Wound odor can be controlled with interval mechanical debridement to decrease the microbial bioburden on the wound surface, with topical antimicrobial therapy (eg, metronidazole) [5-7] and/or with odor-absorbing dressings such as those that have absorptive charcoal within the dressing (eg, Actisorb, Carboflex). Soaks of acetic acid or Dakin solution can also help to minimize odor.

Bleeding — A nonadherent dressing can be placed directly on the friable wound to reduce bleeding and reduce pain associated with dressing changes. A second layer of alginate dressings that contain coagulants can also help to minimize bleeding (table 1).

Chronic wounds that are prone to oozing from the ulcer bed (eg, malignant wounds that cannot be excised) can be controlled with topical hemostatic agents or sucralfate [8] and gentle pressure in the form of elastic bandages, with focal points of bleeding managed with silver nitrate, handheld cautery, or local anesthetic with epinephrine. (See "Overview of topical hemostatic agents and tissue adhesives" and "Subcutaneous infiltration of local anesthetics".)

Pruritus — Itching is a common complaint with chronic wounds. Itching is usually due to dry skin or contact dermatitis. Keeping the skin moisturized and protected will help reduce itching, and, if necessary, topical corticosteroid creams can be applied. (See "Irritant contact dermatitis in adults", section on 'Management'.)

Exudate — An absorptive dressing should be placed over the nonadherent dressing to control drainage and reduce periwound maceration and tailored to the specific anatomic location and wound depth (table 1).

Alternatively, wound drainage can be drawn away using a collecting device (eg, ostomy appliance, negative pressure wound therapy device), provided there are no contraindications. (See "Basic principles of wound management", section on 'Wound debridement' and "Basic principles of wound management", section on 'Wound dressings' and 'Negative pressure wound therapy' below.)

Pain — Pain associated with the wound, and specifically with dressing changes, should not be ignored. The World Health Organization analgesic ladder, which was developed for the treatment of cancer-related pain, is applicable to other types of chronic pain. For patients receiving stable doses of a long-acting opioid around the clock, supplemental doses of a short-acting agent should be considered prior to dressing changes, if they are painful. (See "Cancer pain management with opioids: Optimizing analgesia" and "Cancer pain management: Role of adjuvant analgesics (coanalgesics)" and "Management of acute pain in the patient chronically using opioids for non-cancer pain" and "Approach to the management of chronic non-cancer pain in adults".)

SURGICAL APPROACH — In general, surgical intervention of chronic wounds, which frequently requires multiple staged surgical procedures, is used to prepare the wound bed first by managing infection and handling any underlying factors contributing to wound chronicity (eg, bony deformities, foreign body, biomechanical instability), and then to subsequent coverage of the wound, which may require surgical revascularization. If these are successful in converting the chronic wound to an acute wound, provisional or definitive wound coverage can be performed. (See 'Wound bed preparation' below and 'Wound coverage/closure' below.)

Chronic wounds from cutaneous ulceration that occur in the setting of systemic disease states such as vasoocclusive, autoimmune, and inflammatory disorders (eg, rheumatoid arthritis, sickle cell disease, pyoderma gangrenosum, scleroderma) are difficult to treat and are often colonized with antibiotic-resistant bacteria [9]. Appropriate medical management of the underlying condition must be addressed prior to any planned definitive surgical procedure. As an example, pyoderma gangrenosum is a specific case of a chronic wound where surgical intervention is not typically indicated unless appropriate medical management has first been conducted. (See "Approach to the differential diagnosis of leg ulcers" and "Pyoderma gangrenosum: Treatment and prognosis".)

Surgery has inherent risks associated with the procedure itself as well as anesthesia-related risks. Medical optimization is important to decrease the risk of intraoperative and postoperative complications. The risks and benefits of surgery should be assessed to determine if the surgical intervention is the best course of treatment. Chronic wounds associated with malignancy can often be approached surgically if there are no prohibitive comorbidities and doing so aligns with the patient's goals for care. Even with advanced systemic disease, surgical debridement of the wound is possible.

Some patients may be too sick or disabled to undergo repeated procedures, which are often necessary to achieve wound closure. For debilitated patients with chronic lower extremity ischemia or malignancy-related wounds on the lower extremity, primary amputation may be a more appropriate course of action. (See "Lower extremity amputation".)

WOUND BED PREPARATION — Wound bed preparation is defined as the process of removing local barriers to wound healing to maximize the potential for successful healing. This is accomplished primarily through debridement. Adjunctive methods to aid in preparing the chronic wound bed include negative pressure wound therapy and hyperbaric oxygen therapy, which are discussed briefly below, and in more detail elsewhere. (See 'Operative debridement' below and 'Adjunctive therapies' below.)

Cultures — Obtaining bacterial/fungal/acid fast bacilli cultures may be helpful if there are clinical signs of infection. A random culture will most likely yield a positive result in a chronic wound environment even though it may not be pathogenic [10]. This may lead to unnecessary antibiotic treatment. In addition, biofilm cannot be detected through traditional agar culture methods. Other methods are necessary for biofilm detection such as 16S rDNA pyrosequencing [11]. If there is suspicion of infection (purulence, heavy drainage, clinical signs of infection in the surrounding tissue), a tissue specimen should be obtained during debridement.

Operative debridement — Debridement removes nonviable tissue, pathogens (biofilm), contaminants, and foreign (or other) material and also drains areas of infection. It is important that debridement includes the base of the wound as well as the wound perimeter.

Chronic wounds may require serial debridement in the operating room to sufficiently prepare the wound bed [12]. Clinic-based debridement often does not allow for sufficiently aggressive removal of nonviable tissue and biofilm due to inadequate pain control and the limited ability to achieve hemostasis. The operating room is a safer environment for the debridement of chronic wounds, which often require the management of deeper soft tissue and bone-related issues. In some cases, it is more appropriate to debride the wounds in the operating room, even if no definitive closure/coverage is planned, due to the degree of nonviable tissue/contamination/infection.

For chronic wounds that appear infected, wound/tissue cultures should be obtained during operative debridement to help direct antimicrobial therapy. If the etiology of the wound is unknown or the wound displays atypical characteristics, an excisional biopsy of the wound and/or wound perimeter should be also be obtained for histology.

Adjunctive therapies

Negative pressure wound therapy — Negative pressure wound therapy (NPWT), also called vacuum-assisted wound closure, refers to wound dressing systems that continuously or intermittently apply subatmospheric pressure to the surface of a wound. NPWT promotes the development of granulation tissue to cover deeper exposed tissues [13]. NPWT is primarily used in situations where healing is expected. NPWT can also provide programmable intermittent fluid irrigation between operations [14]. Information regarding the mechanism of action and use of this device and contraindications (eg, malignancy in the wound) for its use is reviewed elsewhere. (See "Negative pressure wound therapy".)

NPWT may improve the healing of some types of chronic wounds/ulceration provided that they are well vascularized [15-17]. Patients with extremity wounds and inadequate peripheral pulses should undergo noninvasive vascular testing to confirm adequate perfusion prior to instituting NPWT, especially patients with diabetes or other risk factors for peripheral artery disease. (See "Noninvasive diagnosis of upper and lower extremity arterial disease".)

Compared with conventional dressing changes, NPWT reduces time to closure of diabetic foot ulcers and wounds resulting from diabetic foot surgery. In this population of patients, NPWT is also associated with shorter length of hospitalization, decreased complication rates, and reduced costs. The use of NPWT in the management of diabetic foot lesions is discussed in detail separately. (See 'Diabetic foot wounds' below.)

Three randomized trials have evaluated the use of NPWT as an adjunctive therapy for the management of pressure (decubitus) ulcers [15,18,19]. No significant differences were identified with respect to quantitative wound healing measures (eg, wound surface area reduction). However, NPWT improved patient comfort and was less labor intensive [20]. (See 'Pressure-induced skin and soft tissue injury' below.)

NPWT has been used instead of traditional bolstering methods to provide skin graft fixation [21,22]. The NPWT dressing distributes negative pressure uniformly over the surface of the fresh graft, immobilizing the graft with less chance of shearing [23]. Improved qualitative skin graft take and quantitative improvements in skin graft success (eg, reduced number of repeat grafts) have been described in observational studies [24-27] and in two randomized trials [28,29]. In one of the trials, 60 patients were randomly assigned to conventional bolster dressing or NPWT following split-thickness skin graft [28]. NPWT was associated with significant reduction in the loss of graft area (0 versus 4.5 cm2 in the control group) and the median duration of hospitalization (13.5 versus 17 days).

The abdominal wall of patients undergoing exploration for severe abdominal trauma is frequently left open to facilitate second-look operations [30,31]. In this patient population, NPWT improves the success of both early and late (>9 days) fascial closure. A general discussion of the management of the open abdomen is found elsewhere. (See 'Abdominal wounds' below.)

Hyperbaric oxygen therapy — Hyperbaric oxygen therapy (HBOT) has been used as an adjunct to wound care in the treatment of chronic wounds [32-38]. HBOT has been shown to have in vitro effects on wound healing [39]. HBOT may also aid wound bed preparation by increasing local tissue oxygen perfusion prior to the definitive surgical procedure, which may be particularly important for wounds that develop as a late effect of radiation therapy for the treatment of cancer [32,40-42]. (See "Hyperbaric oxygen therapy" and "Management of late complications of head and neck cancer and its treatment", section on 'Hyperbaric oxygen'.)

Most studies of HBOT in chronic wounds are observational, and the few available trials are limited by small sample size and low quality [43-45]. Systematic reviews have concluded that, although hyperbaric oxygen may benefit some types of wounds (eg, postradiation therapy), there is insufficient evidence to support routine use [46,47].

Although HBOT has been associated with more rapid ulcer healing in patients with diabetes, the indications for hyperbaric oxygen in the treatment of nonhealing diabetic foot ulcers remain uncertain. Although a number of series and randomized trials of various sizes and quality have suggested its utility, later studies suggest that HBOT has no benefit for diabetic foot ulcer healing and limb salvage [48]. HBOT for the management of diabetic foot ulceration is discussed in detail elsewhere. (See 'Diabetic foot wounds' below.)

Support for HBOT for venous or pressure ulcers, and wounds related to chronic ischemia due to peripheral artery disease, is lacking. (See 'Venous stasis ulcers' below and 'Ischemic ulcers and gangrene' below.)

WOUND COVERAGE/CLOSURE — Surgical procedures that provide wound coverage/closure are briefly described below. It is important to address the underlying etiology prior to performing the definitive procedure.

If the wound is relatively small, it can be completely excised and closed primarily (sutures/staples) provided there is no to minimal skin tension. An understanding of appropriate tension and blood supply is paramount to allow for healing. In a previously infected wound, we avoid placing absorbable sutures deeply within the wound. In this situation, vertical mattress sutures may help bring the deep and superficial spaces together.

Larger or more complicated wounds may require graft or flap coverage. Procedures that provide coverage to the chronic wound are listed below and discussed in more detail in the linked topics.

Split-thickness skin graft – Split-thickness skin grafts (STSGs), also called partial-thickness grafts, are autologous epidermal/dermal grafts. Chronic wounds with a good bed of granulation tissue and without exposed tendon or bone are good candidates for skin grafting. STSGs may be complicated by secondary contracture and should be avoided in areas around joint surfaces. (See "Skin autografting", section on 'Split-thickness skin grafting'.)

Full-thickness skin grafts – Full-thickness skin grafts (FTSGs) are autologous epidermal and full-thickness dermal grafts. These grafts have a decreased incidence of secondary contracture. FTSG is appropriate when a thicker autograft is necessary, such as for deeper wounds or in areas that require more durable tissue (eg, foot). (See "Skin autografting", section on 'Full-thickness skin grafting'.)

Xenografts/allografts – If an autologous graft is not possible, a xenograft or allograft can be used. One strategy is to use a xenograft or allograft to build up a dermal tissue layer prior to STSG application. A xenograft or allograft will be replaced by the host tissue over time. There are a variety of xenografts/allografts that serve different purposes (table 2). Porcine epidermis can be applied to the wound surface as a litmus test to ensure that adequate debridement was performed prior to the definitive closure/coverage procedure, or it can be used as a biologic dressing when there is low confidence in patient compliance. Other xenografts, including bovine collagen, can be used to cover deeper soft tissue defects to form a neodermis in preparation to receive a split-thickness skin graft. Allografts can be used for the same purpose.

Local tissue flaps – Local tissue rearrangement is useful in many circumstances when primary closure is not possible. These techniques involve recruitment of skin from surrounding areas and transposing it into the defect to allow for closure. Blood supply to the flap must be preserved. Common local tissue flaps include V-to-Y advancement, rotation flaps, and advancement flaps. (See "Z-plasty" and "Overview of flaps for soft tissue reconstruction", section on 'Skin'.)

Pedicled flaps – Pedicled flaps are useful when muscle or fascia is needed to cover a large wound or deep wound that has exposed tendon or bone. The blood supply to the harvested muscle must be preserved, and the flap is rotated to cover the wound defect. Pedicled flaps include expendable muscles, such as the abductor hallucis muscle flap for coverage of medial foot or ankle defects, or the hemigastrocnemius muscle flap to cover knee defects. Another common flap is the soleus flap for coverage of mid-tibial defects. (See "Surgical reconstruction of the lower extremity" and "Overview of flaps for soft tissue reconstruction", section on 'Pedicled'.)

Free tissue transfers – Free tissue transfer is an important technique for closure of larger soft tissue defects that may not be amenable to pedicled or local advancement flaps. The muscle or fascia is harvested, with or without the overlying skin, along its vascular pedicle. The free flap is placed into the defect and the arterial and venous blood supply sutured to a local artery and vein nearby. (See "Overview of flaps for soft tissue reconstruction", section on 'Skin'.)

Once a wound is closed or covered, careful surveillance is needed. Recurrence of the wound at the same site or development of wounds at another location can occur after initial healing, especially in high-risk patients. As an example, diabetic patients with peripheral neuropathy must be adequately protected with specialized accommodative inserts, shoes, and braces. Thus, it is important to address as the initial reason for the chronic wound.

SPECIFIC WOUND MANAGEMENT — Management of specific chronic wounds is briefly discussed below.

Diabetic foot wounds — The diabetic foot ulcer is a unique category of chronic wound that requires multiple considerations (algorithm 1). The general evaluation and management of diabetic foot ulcers is discussed separately [49]. (See "Evaluation of the diabetic foot" and "Management of diabetic foot ulcers".)

Chronic diabetic foot ulcers are often colonized with a variety of pathogens. For patients who require operative debridement, or incision and drainage for infection, initial empiric antibiotic therapy is transitioned to more specific treatment based upon the results and sensitivities of intraoperative cultures. Prolonged antibiotic therapy may be needed, particularly for the treatment of osteomyelitis [50]. Further, specific therapy, such as negative pressure wound therapy, should be considered before surgery and in between surgical debridements [51-53]. (See "Management of diabetic foot ulcers", section on 'Managing infection'.)

Special attention should also be given to identifying and correcting any underlying bony deformities or biomechanical instability causing areas of focal pressure or shear stress as the source of delayed wound healing. Correction may require adjunctive surgery (eg, Achilles tendon lengthening to offload the plantar forefoot, free or pedicled flap to provide tissue durability) or more complex bony reconstruction/realignment. (See "Management of diabetic foot ulcers", section on 'Mechanical offloading'.)

The weightbearing nature of the foot increases the risk for wound recurrence after closure/coverage, particularly when a skin graft is used, since these are insensate. The surgical plan should address durability and the demands of ambulation. The patient will also require long-term use of a custom shoe with an accommodative orthotic. Bracing with an ankle-foot orthosis may also be necessary to reduce the risk for recurrence [54]. (See "Management of diabetic foot ulcers", section on 'Mechanical offloading'.)

The following case examples illustrate different types of diabetic foot wounds.

The pictures in the figure show the management of a diabetic patient with a diabetic foot infection (picture 1). Following incision and drainage of the ankle joint and debridement of necrotic skin, the postsurgical wound was managed with wound dressings, followed by skin grafting.

The pictures in the figure show the management of a diabetic patient with a chronic sinus draining from the plantar aspect of the foot that was present for over nine months. Following debridement, the wound was dressed and treated with a matrix wound dressing to provide an appropriate wound bed for skin grafting (picture 2). After two weeks, the overlying silicone layer was removed and a skin graft was placed (picture 3).

Ischemic ulcers and gangrene — The presence of ischemia influences the timing of revascularization, debridement, and definitive coverage/closure.

For patients with wet gangrene or abscess (picture 4), the wound should be debrided immediately regardless of the need for revascularization. The dressing choice depends upon the level of anticipated drainage and the size of the wound. Dead space is usually managed with gauze packing. The extremity should be revascularized as soon as safely possible, if needed, after drainage/debridement and control of the infection.

For patients with dry gangrene without cellulitis (picture 5), the limb should be revascularized first. The wound dressing is protective, reducing the risk for trauma or infection. The wound should be lightly wrapped with a bulky dry gauze bandage, avoiding excess pressure that could aggravate ischemia. Following revascularization, the wound should be monitored closely for signs of healing or for tissue necrosis/drainage that may indicate a need for further debridement.

Chronic orthopedic wounds — Large soft tissue defects of the extremities are often the result of trauma and are frequently accompanied by bony fractures. When traumatic wounds become chronic, wound coverage options are dictated by the severity of the initial injury and the anatomic location. (See "Severe lower extremity injury in the adult patient" and "Surgical reconstruction of the lower extremity".)

For traumatic wounds that required internal fixation, the chronicity of the wound may be due to an underlying bone infection (osteomyelitis) or biofilm on a screw, plate, anchor, or heavy suture. Thus, removal of affected materials will be necessary for definitive closure. Bone infection requires resection of the infected segment, long-term antibiotics, and/or use of antibiotic-impregnated cement. The skeletal framework must be addressed to provide stability of the overlying soft tissue envelope. Treatment of chronic or subacute osteomyelitis can occur over many months with standard antibiotic treatment regimens lasting typically six weeks, following a period of time off antibiotics, at which time bone culture is repeated. If the repeat culture or aspirate is negative, definitive soft tissue closure/coverage can proceed. (See "Nonvertebral osteomyelitis in adults: Clinical manifestations and diagnosis".)

Total joint implants pose a difficult problem. Expeditious soft tissue coverage or closure over noninfected joint implants or internal fixation is important. Infected internal fixation constructs and joint implants may require removal with subsequent reimplantation once the infection is resolved. Typically, these problems require pedicled flaps or free tissue transfers for definitive coverage. (See 'Wound coverage/closure' above and "Skin autografting" and "Surgical reconstruction of the lower extremity".)

The following case examples illustrate different types of chronic orthopedic wounds.

The pictures in the figure show the management of a patient with an infected total knee arthroplasty (picture 6). Four weeks after the procedure, the incision site evidenced drainage and was opened. Following debridement of necrotic tissue, a rotation flap was used to close the open knee defect, over which a skin graft was placed to provide coverage of the muscle.

The pictures in the figure show the management of a patient with a chronic draining sinus three years after open reduction and internal fixation for a fibular fracture (picture 7). After debridement and removal of the previously placed fibular plate, a location rotation flap was used to cover the exposed bone, over which a skin graft was placed to provide coverage of the residual exposed subcutaneous tissue.

The pictures in the figure show the management of patient with a chronic draining sinus related to repair of a prior calcaneal fracture one year previously (picture 8). Following incision, drainage, debridement, and removal of infected hardware, a free flap was placed.

The pictures in the figure show the management of a patient with chronic draining sinus emanating from osteomyelitis in a bone sequestrum following a prior traumatic injury (picture 9). Following bone debridement and removal of the sequestrum, the bone was packed with an antibiotic spacer and a free muscle flap used to provide coverage, over which a skin graft was used to cover the muscle.

Abdominal wounds — A chronic open abdominal wound can occur following local skin separation, partial fascial dehiscence, or complete fascial dehiscence leading to evisceration from an abdominal incision. More often, open abdominal wounds result from intentionally leaving an abdominal incision open at the completion of an abdominal procedure to prevent abdominal compartment syndrome. Rarely, large defects are the result of traumatic injury (eg, shotgun blast).

If the wound is small and the fascia is intact, local wound care with bedside incision and drainage may be all that is needed. Negative pressure wound therapy can aid the closure of clean abdominal wounds. For wounds that are larger, those that have drainage, and those with abdominal wall necrosis, surgical debridement and sequential second-look procedures are more optimal for achieving definitive closure (algorithm 2). (See "Surgical management of necrotizing soft tissue infections" and "Management of the open abdomen in adults".)

The following case examples illustrate different types of chronic abdominal wounds.

The pictures in the figure show the management of a patient with a necrotizing abdominal wall infection related to a surgical site infection. Following debridement of infected and necrotic material (picture 10), including the fascial edges, the wound was able to be closed primarily.

The pictures in the figure show the management of a child with a nonhealing abdominal wall wound that was present for five months (picture 11). The wound was treated with open dressings until a bed of granulation tissue was present, after which a xenograft was initially placed to ensure that a skin graft would take. Negative pressure wound therapy was used to secure the xenograft. A skin graft was placed five days later with a good result.

Pressure-induced skin and soft tissue injury — Pressure-induced injury is due to chronic pressure in susceptible areas that lead to ischemia and skin loss. Sacral, ischial, and trochanteric wounds occur primarily in patients who are wheelchair- or bed-bound. Heel pressure ulcers can also occur in patients who are in bed for prolonged periods of time without offloading devices to the heel. The treatment of pressure ulcers depends upon the stage of the ulcer. (See "Clinical staging and management of pressure-induced skin and soft tissue injury".)

The root cause of the pressure-induced chronic wound must be identified and addressed. If nothing is changed to address the cause, surgical intervention is likely to fail. Prior to surgical flap closure, nutrition must be optimized and the affected surfaces offloaded. For wounds in the perineal region, stool and urinary diversion are a necessary adjunct to care. (See "Surgical management of pressure-induced skin and soft tissue injuries".)

Ulcerated and fungating malignancy-related wounds — The palliative treatment of malignancy-related (eg, post radiation therapy) or ulcerating or fungating malignant wounds represents a clinical challenge without evidence-based guidelines or established protocols. The clinician should establish goals for wound management with the patient. Although symptom management strategies for comfort may work in tandem with healing interventions with the goal of eventual wound closure, it is important to recognize when efforts toward wound closure may become unrealistic or burdensome for the patient.

Topical wound care and specific dressings should be tailored to the individual wound and patient needs, and the physician should appreciate that proper wound management can make a great deal of difference to the patient and influence his or her ability to comfortably receive guests, participate in public events, and assist with activities of daily living [55-58]. Simple wound care such as washing with soap and water and light debridement can be helpful. Often, dressings, such as acetic acid or Dakin solution, are used to aid in odor management. (See 'Local care of chronic wounds' above.)

If feasible, palliative oncologic approaches such as appropriate chemotherapy or radiation therapy can also aid in decreasing tumor burden. If consistent with the goals of care, surgical management may be considered. Surgical options for ulcerated and fungating malignancy-related wounds include surgical resection with appropriate flap or graft reconstruction. Resection and closure may be especially helpful to maintain function for malignant wounds in certain areas of the body, such as in the extremities or groin. However, the decision to operate in such cases must be individualized and include careful consideration of the risks and potential benefits of surgery in the context of the overall disease status and burden as well as the individual patient's goals of care. (See "Benefits, services, and models of subspecialty palliative care", section on 'Establishing goals of care' and "Discussing goals of care".)

The pictures in the figure show the management of a patient with a chronic wound following excision and radiation treatment for invasive squamous carcinoma of the left lower extremity five years before presentation (picture 12). Following 20 courses of hyperbaric oxygen therapy over 20 days, surgical debridement, and open wound dressings, the wound started to heal.

Venous stasis ulcers — The mainstay of treatment for venous ulceration is local wound care and compression therapy. Skin grafting may improve ulcer healing and is indicated for those who do not exhibit appropriate wound healing after 12 months of medical care. (See "Medical management of lower extremity chronic venous disease", section on 'Ulcer care'.)

Venous ulcers are typically colonized with gram-negative bacteria, which uncommonly become planktonic or cause ascending infection or sepsis [59]. Clearance of biofilm, which is also particularly common in venous stasis wounds, is important prior to definitive coverage or closure. Clearance of biofilm is suggested when there is no odor, no discolored drainage, and the wound bed is pink with granulation tissue. Venous ulcers can be very large or even circumferential around the extremity. Thus, surgical intervention often includes the use of skin grafts. Graft adherence is a good sign that biofilm has been eradicated.

Compression therapy is necessary after surgical intervention, including long-term compression therapy to prevent recurrence (picture 13). Ablation of axial veins or perforating veins may be needed to eliminate underlying superficial venous insufficiency [60]. (See "Compression therapy for the treatment of chronic venous insufficiency" and "Approach to treating symptomatic superficial venous insufficiency".)

SOCIETY GUIDELINE LINKS — Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See "Society guideline links: Chronic wound management".)

SUMMARY AND RECOMMENDATIONS

A chronic wound may be defined as one that is physiologically impaired due to a disruption of the wound healing cycle. Wound healing normally progresses at a sustained, measurable rate. A chronic state is defined by some as a less than 15 percent reduction of the surface area of the wound over one week, or less than 50 percent reduction over one month. (See 'Introduction' above.)

Local care of chronic wounds includes debridement and proper wound dressings. Local treatment should also be directed toward dealing with the most troublesome chronic wound problems that affect the patient physically and emotionally, such as odor, bleeding, itching, excess exudate, pain, and minimizing infection. Adjuncts to wound healing may include negative pressure wound therapy and hyperbaric oxygen therapy, provided there are no contraindications for their use. (See 'Local care of chronic wounds' above and 'Negative pressure wound therapy' above and 'Hyperbaric oxygen therapy' above.)

In general, surgical intervention for chronic wounds may be necessary to manage infection, handle any underlying factors that are contributing to the chronic wound state (eg, bony deformities, foreign body, biomechanical instability), and prepare the wound bed for subsequent coverage, which may require repeated procedures and sometimes surgical revascularization. (See 'Surgical approach' above.)

Limited chronic wounds may be amenable to complete excision and primary closure (sutures/staples), provided there is no to minimal skin tension. Larger or more complicated wounds may require skin graft or skin/muscle flap coverage. (See 'Wound coverage/closure' above.)

The management of specific chronic wounds, including diabetic foot wounds, chronic orthopedic wounds, chronic abdominal wounds, pressure ulcers, ulcerated and fungating malignancy-related wounds, and venous ulcers, is briefly reviewed above. (See 'Specific wound management' above.)

Clinical follow-up and wound surveillance are needed once the chronic wound has been closed or covered. Wound recurrence can occur after initial healing, particularly in high-risk populations, such as in patients with diabetic foot wounds. To prevent recurrence, it is important to address the factors that were responsible for the development of the wound. (See 'Wound coverage/closure' above.)

REFERENCES

  1. Golinko MS, Clark S, Rennert R, et al. Wound emergencies: the importance of assessment, documentation, and early treatment using a wound electronic medical record. Ostomy Wound Manage 2009; 55:54.
  2. Sheehan P, Jones P, Giurini JM, et al. Percent change in wound area of diabetic foot ulcers over a 4-week period is a robust predictor of complete healing in a 12-week prospective trial. Plast Reconstr Surg 2006; 117:239S.
  3. Brem H, Balledux J, Bloom T, et al. Healing of diabetic foot ulcers and pressure ulcers with human skin equivalent: a new paradigm in wound healing. Arch Surg 2000; 135:627.
  4. Brem H, Jacobs T, Vileikyte L, et al. Wound-healing protocols for diabetic foot and pressure ulcers. Surg Technol Int 2003; 11:85.
  5. Wood DK. The draining malignant ulceration. Palliative management in advanced cancer. JAMA 1980; 244:820.
  6. Finlay IG, Bowszyc J, Ramlau C, Gwiezdzinski Z. The effect of topical 0.75% metronidazole gel on malodorous cutaneous ulcers. J Pain Symptom Manage 1996; 11:158.
  7. Ashford R, Plant G, Maher J, Teare L. Double-blind trial of metronidazole in malodorous ulcerating tumours. Lancet 1984; 1:1232.
  8. Masuelli L, Tumino G, Turriziani M, et al. Topical use of sucralfate in epithelial wound healing: clinical evidences and molecular mechanisms of action. Recent Pat Inflamm Allergy Drug Discov 2010; 4:25.
  9. Shanmugam VK, Schilling A, Germinario A, et al. Prevalence of immune disease in patients with wounds presenting to a tertiary wound healing centre. Int Wound J 2012; 9:403.
  10. Sadeghpour Heravi F, Zakrzewski M, Vickery K, et al. Bacterial Diversity of Diabetic Foot Ulcers: Current Status and Future Prospectives. J Clin Med 2019; 8.
  11. Wolcott RD, Hanson JD, Rees EJ, et al. Analysis of the chronic wound microbiota of 2,963 patients by 16S rDNA pyrosequencing. Wound Repair Regen 2016; 24:163.
  12. Schultz GS, Sibbald RG, Falanga V, et al. Wound bed preparation: a systematic approach to wound management. Wound Repair Regen 2003; 11 Suppl 1:S1.
  13. Armstrong DG, Lavery LA, Diabetic Foot Study Consortium. Negative pressure wound therapy after partial diabetic foot amputation: a multicentre, randomised controlled trial. Lancet 2005; 366:1704.
  14. Kim PJ, Attinger CE, Steinberg JS, et al. The impact of negative-pressure wound therapy with instillation compared with standard negative-pressure wound therapy: a retrospective, historical, cohort, controlled study. Plast Reconstr Surg 2014; 133:709.
  15. Joseph E, Hamori CA, Berman S, et al. A prospective randomized trial of vacuum-assisted closure versus standard therapy of chronic non-healing wounds. Wounds 2000; 12:60.
  16. Kanakaris NK, Thanasas C, Keramaris N, et al. The efficacy of negative pressure wound therapy in the management of lower extremity trauma: review of clinical evidence. Injury 2007; 38 Suppl 5:S9.
  17. Vuerstaek JD, Vainas T, Wuite J, et al. State-of-the-art treatment of chronic leg ulcers: A randomized controlled trial comparing vacuum-assisted closure (V.A.C.) with modern wound dressings. J Vasc Surg 2006; 44:1029.
  18. Ford CN, Reinhard ER, Yeh D, et al. Interim analysis of a prospective, randomized trial of vacuum-assisted closure versus the healthpoint system in the management of pressure ulcers. Ann Plast Surg 2002; 49:55.
  19. Wanner MB, Schwarzl F, Strub B, et al. Vacuum-assisted wound closure for cheaper and more comfortable healing of pressure sores: a prospective study. Scand J Plast Reconstr Surg Hand Surg 2003; 37:28.
  20. Mandal A. Role of topical negative pressure in pressure ulcer management. J Wound Care 2007; 16:33.
  21. Bovill E, Banwell PE, Teot L, et al. Topical negative pressure wound therapy: a review of its role and guidelines for its use in the management of acute wounds. Int Wound J 2008; 5:511.
  22. Jeschke MG, Rose C, Angele P, et al. Development of new reconstructive techniques: use of Integra in combination with fibrin glue and negative-pressure therapy for reconstruction of acute and chronic wounds. Plast Reconstr Surg 2004; 113:525.
  23. Schneider AM, Morykwas MJ, Argenta LC. A new and reliable method of securing skin grafts to the difficult recipient bed. Plast Reconstr Surg 1998; 102:1195.
  24. Barendse-Hofmann MG, van Doorn L, Steenvoorde P. Circumferential application of VAC on a large degloving injury on the lower extremity. J Wound Care 2009; 18:79.
  25. DeFranzo AJ, Marks MW, Argenta LC, Genecov DG. Vacuum-assisted closure for the treatment of degloving injuries. Plast Reconstr Surg 1999; 104:2145.
  26. Molnar JA, DeFranzo AJ, Marks MW. Single-stage approach to skin grafting the exposed skull. Plast Reconstr Surg 2000; 105:174.
  27. Scherer LA, Shiver S, Chang M, et al. The vacuum assisted closure device: a method of securing skin grafts and improving graft survival. Arch Surg 2002; 137:930.
  28. Llanos S, Danilla S, Barraza C, et al. Effectiveness of negative pressure closure in the integration of split thickness skin grafts: a randomized, double-masked, controlled trial. Ann Surg 2006; 244:700.
  29. Moisidis E, Heath T, Boorer C, et al. A prospective, blinded, randomized, controlled clinical trial of topical negative pressure use in skin grafting. Plast Reconstr Surg 2004; 114:917.
  30. Stevens P. Vacuum-assisted closure of laparostomy wounds: a critical review of the literature. Int Wound J 2009; 6:259.
  31. Rotondo MF, Schwab CW, McGonigal MD, et al. 'Damage control': an approach for improved survival in exsanguinating penetrating abdominal injury. J Trauma 1993; 35:375.
  32. Niezgoda JA, Serena TE, Carter MJ. Outcomes of Radiation Injuries Using Hyperbaric Oxygen Therapy: An Observational Cohort Study. Adv Skin Wound Care 2016; 29:12.
  33. Tibbles PM, Edelsberg JS. Hyperbaric-oxygen therapy. N Engl J Med 1996; 334:1642.
  34. Wattel F, Mathieu D, Nevière R, Bocquillon N. Acute peripheral ischaemia and compartment syndromes: a role for hyperbaric oxygenation. Anaesthesia 1998; 53 Suppl 2:63.
  35. Leach RM, Rees PJ, Wilmshurst P. Hyperbaric oxygen therapy. BMJ 1998; 317:1140.
  36. Oriani G, Meazza D, Favales F, et al. Hyperbaric therapy in diabetic gangrene. J Hyperb Med 1990; 5:171.
  37. Hammarlund C, Sundberg T. Hyperbaric oxygen reduced size of chronic leg ulcers: a randomized double-blind study. Plast Reconstr Surg 1994; 93:829.
  38. Löndahl M, Katzman P, Nilsson A, et al. A prospective study: hyperbaric oxygen therapy in diabetics with chronic foot ulcers. J Wound Care 2006; 15:457.
  39. Thom SR. Hyperbaric oxygen: its mechanisms and efficacy. Plast Reconstr Surg 2011; 127 Suppl 1:131S.
  40. Bennett MH, Feldmeier J, Hampson N, et al. Hyperbaric oxygen therapy for late radiation tissue injury. Cochrane Database Syst Rev 2005; :CD005005.
  41. Bennett MH, Feldmeier J, Hampson N, et al. Hyperbaric oxygen therapy for late radiation tissue injury. Cochrane Database Syst Rev 2012; :CD005005.
  42. Hoggan BL, Cameron AL. Systematic review of hyperbaric oxygen therapy for the treatment of non-neurological soft tissue radiation-related injuries. Support Care Cancer 2014; 22:1715.
  43. Kessler L, Bilbault P, Ortéga F, et al. Hyperbaric oxygenation accelerates the healing rate of nonischemic chronic diabetic foot ulcers: a prospective randomized study. Diabetes Care 2003; 26:2378.
  44. Duzgun AP, Satir HZ, Ozozan O, et al. Effect of hyperbaric oxygen therapy on healing of diabetic foot ulcers. J Foot Ankle Surg 2008; 47:515.
  45. Abidia A, Laden G, Kuhan G, et al. The role of hyperbaric oxygen therapy in ischaemic diabetic lower extremity ulcers: a double-blind randomised-controlled trial. Eur J Vasc Endovasc Surg 2003; 25:513.
  46. Wang C, Schwaitzberg S, Berliner E, et al. Hyperbaric oxygen for treating wounds: a systematic review of the literature. Arch Surg 2003; 138:272.
  47. Kranke P, Bennett MH, Martyn-St James M, et al. Hyperbaric oxygen therapy for chronic wounds. Cochrane Database Syst Rev 2012; :CD004123.
  48. Margolis DJ, Gupta J, Hoffstad O, et al. Lack of effectiveness of hyperbaric oxygen therapy for the treatment of diabetic foot ulcer and the prevention of amputation: a cohort study. Diabetes Care 2013; 36:1961.
  49. Mills JL Sr, Conte MS, Armstrong DG, et al. The Society for Vascular Surgery Lower Extremity Threatened Limb Classification System: risk stratification based on wound, ischemia, and foot infection (WIfI). J Vasc Surg 2014; 59:220.
  50. Lipsky BA, Berendt AR, Cornia PB, et al. Executive summary: 2012 Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections. Clin Infect Dis 2012; 54:1679.
  51. Kim PJ, Attinger CE, Steinberg JS, Evans KK. Negative Pressure Wound Therapy with Instillation: Past, Present, and Future. Surg Technol Int 2015; 26:51.
  52. Dalla Paola L. Diabetic foot wounds: the value of negative pressure wound therapy with instillation. Int Wound J 2013; 10 Suppl 1:25.
  53. Kim PJ, Attinger CE, Oliver N, et al. Comparison of Outcomes for Normal Saline and an Antiseptic Solution for Negative-Pressure Wound Therapy with Instillation. Plast Reconstr Surg 2015; 136:657e.
  54. Paton J, Bruce G, Jones R, Stenhouse E. Effectiveness of insoles used for the prevention of ulceration in the neuropathic diabetic foot: a systematic review. J Diabetes Complications 2011; 25:52.
  55. Seaman S. Management of malignant fungating wounds in advanced cancer. Semin Oncol Nurs 2006; 22:185.
  56. Merz T, Klein C, Uebach B, et al. Fungating Wounds - Multidimensional Challenge in Palliative Care. Breast Care (Basel) 2011; 6:21.
  57. Zech DF, Grond S, Lynch J, et al. Validation of World Health Organization Guidelines for cancer pain relief: a 10-year prospective study. Pain 1995; 63:65.
  58. Adderley UJ, Holt IG. Topical agents and dressings for fungating wounds. Cochrane Database Syst Rev 2014; :CD003948.
  59. Renner R, Sticherling M, Rüger R, Simon J. Persistence of bacteria like Pseudomonas aeruginosa in non-healing venous ulcers. Eur J Dermatol 2012; 22:751.
  60. Thakral G, La Fontaine J, Kim P, et al. Treatment options for venous leg ulcers: effectiveness of vascular surgery, bioengineered tissue, and electrical stimulation. Adv Skin Wound Care 2015; 28:164.
Topic 99040 Version 12.0

References

1 : Wound emergencies: the importance of assessment, documentation, and early treatment using a wound electronic medical record.

2 : Percent change in wound area of diabetic foot ulcers over a 4-week period is a robust predictor of complete healing in a 12-week prospective trial.

3 : Healing of diabetic foot ulcers and pressure ulcers with human skin equivalent: a new paradigm in wound healing.

4 : Wound-healing protocols for diabetic foot and pressure ulcers.

5 : The draining malignant ulceration. Palliative management in advanced cancer.

6 : The effect of topical 0.75% metronidazole gel on malodorous cutaneous ulcers.

7 : Double-blind trial of metronidazole in malodorous ulcerating tumours.

8 : Topical use of sucralfate in epithelial wound healing: clinical evidences and molecular mechanisms of action.

9 : Prevalence of immune disease in patients with wounds presenting to a tertiary wound healing centre.

10 : Bacterial Diversity of Diabetic Foot Ulcers: Current Status and Future Prospectives.

11 : Analysis of the chronic wound microbiota of 2,963 patients by 16S rDNA pyrosequencing.

12 : Wound bed preparation: a systematic approach to wound management.

13 : Negative pressure wound therapy after partial diabetic foot amputation: a multicentre, randomised controlled trial.

14 : The impact of negative-pressure wound therapy with instillation compared with standard negative-pressure wound therapy: a retrospective, historical, cohort, controlled study.

15 : A prospective randomized trial of vacuum-assisted closure versus standard therapy of chronic non-healing wounds

16 : The efficacy of negative pressure wound therapy in the management of lower extremity trauma: review of clinical evidence.

17 : State-of-the-art treatment of chronic leg ulcers: A randomized controlled trial comparing vacuum-assisted closure (V.A.C.) with modern wound dressings.

18 : Interim analysis of a prospective, randomized trial of vacuum-assisted closure versus the healthpoint system in the management of pressure ulcers.

19 : Vacuum-assisted wound closure for cheaper and more comfortable healing of pressure sores: a prospective study.

20 : Role of topical negative pressure in pressure ulcer management.

21 : Topical negative pressure wound therapy: a review of its role and guidelines for its use in the management of acute wounds.

22 : Development of new reconstructive techniques: use of Integra in combination with fibrin glue and negative-pressure therapy for reconstruction of acute and chronic wounds.

23 : A new and reliable method of securing skin grafts to the difficult recipient bed.

24 : Circumferential application of VAC on a large degloving injury on the lower extremity.

25 : Vacuum-assisted closure for the treatment of degloving injuries.

26 : Single-stage approach to skin grafting the exposed skull.

27 : The vacuum assisted closure device: a method of securing skin grafts and improving graft survival.

28 : Effectiveness of negative pressure closure in the integration of split thickness skin grafts: a randomized, double-masked, controlled trial.

29 : A prospective, blinded, randomized, controlled clinical trial of topical negative pressure use in skin grafting.

30 : Vacuum-assisted closure of laparostomy wounds: a critical review of the literature.

31 : 'Damage control': an approach for improved survival in exsanguinating penetrating abdominal injury.

32 : Outcomes of Radiation Injuries Using Hyperbaric Oxygen Therapy: An Observational Cohort Study.

33 : Hyperbaric-oxygen therapy.

34 : Acute peripheral ischaemia and compartment syndromes: a role for hyperbaric oxygenation.

35 : Hyperbaric oxygen therapy.

36 : Hyperbaric therapy in diabetic gangrene

37 : Hyperbaric oxygen reduced size of chronic leg ulcers: a randomized double-blind study.

38 : A prospective study: hyperbaric oxygen therapy in diabetics with chronic foot ulcers.

39 : Hyperbaric oxygen: its mechanisms and efficacy.

40 : Hyperbaric oxygen therapy for late radiation tissue injury.

41 : Hyperbaric oxygen therapy for late radiation tissue injury.

42 : Systematic review of hyperbaric oxygen therapy for the treatment of non-neurological soft tissue radiation-related injuries.

43 : Hyperbaric oxygenation accelerates the healing rate of nonischemic chronic diabetic foot ulcers: a prospective randomized study.

44 : Effect of hyperbaric oxygen therapy on healing of diabetic foot ulcers.

45 : The role of hyperbaric oxygen therapy in ischaemic diabetic lower extremity ulcers: a double-blind randomised-controlled trial.

46 : Hyperbaric oxygen for treating wounds: a systematic review of the literature.

47 : Hyperbaric oxygen therapy for chronic wounds.

48 : Lack of effectiveness of hyperbaric oxygen therapy for the treatment of diabetic foot ulcer and the prevention of amputation: a cohort study.

49 : The Society for Vascular Surgery Lower Extremity Threatened Limb Classification System: risk stratification based on wound, ischemia, and foot infection (WIfI).

50 : Executive summary: 2012 Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections.

51 : Negative Pressure Wound Therapy with Instillation: Past, Present, and Future.

52 : Diabetic foot wounds: the value of negative pressure wound therapy with instillation.

53 : Comparison of Outcomes for Normal Saline and an Antiseptic Solution for Negative-Pressure Wound Therapy with Instillation.

54 : Effectiveness of insoles used for the prevention of ulceration in the neuropathic diabetic foot: a systematic review.

55 : Management of malignant fungating wounds in advanced cancer.

56 : Fungating Wounds - Multidimensional Challenge in Palliative Care.

57 : Validation of World Health Organization Guidelines for cancer pain relief: a 10-year prospective study.

58 : Topical agents and dressings for fungating wounds.

59 : Persistence of bacteria like Pseudomonas aeruginosa in non-healing venous ulcers.

60 : Treatment options for venous leg ulcers: effectiveness of vascular surgery, bioengineered tissue, and electrical stimulation.